Abstract
Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness, cataplexy, hypnagogic hallucinations, and sleep-onset rapid eye movement (REM) sleep periods. Narcolepsy is now identified to be a neurodegenerative disease, as there is a massive loss of neurons containing the neuropeptide, hypocretin/orexin. Orexin neurons are solely located in the hypothalamus, particularly in its perifornical, dorsomedial and lateral portions. Orexin fibers widely project throughout the brain and generally have excitatory effects on their postsynaptic cells. Patients with narcolepsy have a severe reduction in the levels of orexins in the cerebrospinal fluid, a finding consistent with orexin neuronal loss. Experimental models have been generated in order to study the physiology of the orexin system and narcolepsy. The discovery of orexin deficiency in narcolepsy is redefining the clinical entity of narcolepsy and offering novel diagnostic procedures. This article reviews the current understanding of narcolepsy and discusses the opportunity to explore the potential use of transplants as a therapeutical tool in order to treat narcolepsy.
Keywords: hypocretin/orexin neurons, narcolepsy, sleep, lateral hypothalamus, animal models, cell transplant
CNS & Neurological Disorders - Drug Targets
Title: Cell Transplantation: A Future Therapy for Narcolepsy?
Volume: 8 Issue: 4
Author(s): Oscar Arias-Carrion and Eric Murillo-Rodriguez
Affiliation:
Keywords: hypocretin/orexin neurons, narcolepsy, sleep, lateral hypothalamus, animal models, cell transplant
Abstract: Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness, cataplexy, hypnagogic hallucinations, and sleep-onset rapid eye movement (REM) sleep periods. Narcolepsy is now identified to be a neurodegenerative disease, as there is a massive loss of neurons containing the neuropeptide, hypocretin/orexin. Orexin neurons are solely located in the hypothalamus, particularly in its perifornical, dorsomedial and lateral portions. Orexin fibers widely project throughout the brain and generally have excitatory effects on their postsynaptic cells. Patients with narcolepsy have a severe reduction in the levels of orexins in the cerebrospinal fluid, a finding consistent with orexin neuronal loss. Experimental models have been generated in order to study the physiology of the orexin system and narcolepsy. The discovery of orexin deficiency in narcolepsy is redefining the clinical entity of narcolepsy and offering novel diagnostic procedures. This article reviews the current understanding of narcolepsy and discusses the opportunity to explore the potential use of transplants as a therapeutical tool in order to treat narcolepsy.
Export Options
About this article
Cite this article as:
Arias-Carrion Oscar and Murillo-Rodriguez Eric, Cell Transplantation: A Future Therapy for Narcolepsy?, CNS & Neurological Disorders - Drug Targets 2009; 8 (4) . https://dx.doi.org/10.2174/187152709788921681
DOI https://dx.doi.org/10.2174/187152709788921681 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
SLC1 Glutamate Transporters and Diseases: Psychiatric Diseases and Pathological Pain
Current Molecular Pharmacology An Insight Into Mitochondrial Dysfunction and its Implications in Neurological Diseases
Current Drug Targets n-3 Fatty Acids: Role in Neurogenesis and Neuroplasticity
Current Medicinal Chemistry Zinc Homeostasis-regulating Proteins: New Drug Targets for Triggering Cell Fate
Current Drug Targets Perspectives on the Tertiary Prevention Strategy for Alzheimer’s Disease
Current Alzheimer Research Protein O-GlcNAcylation: A Critical Regulator of the Cellular Response to Stress
Current Signal Transduction Therapy Patent Selections
Recent Patents on DNA & Gene Sequences Recent Approaches to Novel Anti-Alzheimer Therapy
Current Pharmaceutical Design The Anticholinesterase Activity of Three Local Food Spices and Their Anti-Alzheimer Application
Current Nutraceuticals Metabolism of the Endocannabinoids Anandamide and 2-Arachidonoyl Glycerol, A Review, with Emphasis on the Pharmacology of Fatty Acid Amide Hydrolase, A Possible Target for the Treatment of Neurodegenerative Diseases and Pain
Current Medicinal Chemistry - Central Nervous System Agents Relevance of Dopamine D2/Neurotensin NTS1 and NMDA/Neurotensin NTS1 Receptor Interaction in Psychiatric and Neurodegenerative Disorders
Current Medicinal Chemistry Attenuating Muscle Wasting: Cell and Gene Therapy Approaches
Current Genomics Resveratrol Rescues Tau-Induced Cognitive Deficits and Neuropathology in a Mouse Model of Tauopathy
Current Alzheimer Research Salen Mn Complexes are Superoxide Dismutase/Catalase Mimetics that Protect the Mitochondria
Current Inorganic Chemistry (Discontinued) FoxO3a Governs Early Microglial Proliferation and Employs Mitochondrial Depolarization with Caspase 3, 8, and 9 Cleavage During Oxidant Induced Apoptosis
Current Neurovascular Research Hypoxia as an Initiator of Neuroinflammation: Microglial Connections
Current Neuropharmacology Astrocytes: From the Physiology to the Disease
Current Alzheimer Research Enhanced Hippocampal Neurogenesis in APP/Ps1 Mouse Model of Alzheimer's Disease After Implantation of VEGF-loaded PLGA Nanospheres
Current Alzheimer Research Recent Patents Review on Intranasal Administration for CNS Drug Delivery
Recent Patents on Drug Delivery & Formulation Tetracyclines and Pulmonary Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets